Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response

By  

Acta Haematologica, Vol. 136, Iss. 1, 2016-05 ,pp. : 45-51

Karger

Access to resources Recommend Favorite

Changes in Expression of Apoptosis-Related Genes Are Linked to the Molecular Response to Imatinib Treatment in Chronic-Phase Chronic Myeloid Leukemia Patients

By  

Acta Haematologica, Vol. 117, Iss. 2, 2006-11 ,pp. : 83-90

Karger

Access to resources Recommend Favorite

Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting

By Saleh Mansoor N.   Haislip Sally   Sharpe Joyce   Hess Tamara   Gilmore James   Jackson James   Sail Kavita R.   Ericson Solveig G.   Chen Lei  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 529-536

Informa Healthcare

Access to resources Recommend Favorite

The Importance of Body Surface Area at Baseline and during Treatment in Chronic Myeloid Leukemia Patients Treated with Imatinib

By  

Acta Haematologica, Vol. 134, Iss. 1, 2015-04 ,pp. : 57-58

Karger

Access to resources Recommend Favorite

Continuing Imatinib Treatment for Chronic Myeloid Leukemia Patients Who Had Serious Adverse Events at the Onset of Therapy

By  

Acta Haematologica, Vol. 137, Iss. 3, 2017-04 ,pp. : 158-162

Karger

Access to resources Recommend Favorite